Arvinas ARV-471 ER Degrader

CRBN-based heterobifunctional ER degrader

oral Ph. II candidate for ER+/HER2- BC

from ER ligand and CRBN ligand


Arvinas, New Haven, CT

The Arvinas ER chimeric degrader, ARV-471, is an oral, bioavailable ER degrading CRBN-based  PROTAC for the treatment of patients with ER+/HER2- breast cancer. Along with ARV-110, it is one…

     this content is exclusive to
    Premium members

    Upgrade to a Premium Drug Hunter membership to unlock the full content and start reading now.